Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vimseltinib P-gp Inhibition Study in Healthy Males
NCT07744802Phase 1Recruiting
- Sponsor
- Deciphera Pharmaceuticals
- Start
- Sep 2026
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of vimseltinib, sponsored by Deciphera Pharmaceuticals. Primary endpoints: Maximum Observed Plasma Drug Concentration of Dabigatran, Area Under the Plasma Concentration-Time Curve from Time 0 up to Time t of Dabigatran and 1 more. Started Sep 2026; status: recruiting.
02
Drugs
vimseltinib
Beyond the preview
Go deeper on NCT07744802.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07744802.